AlloVir (ALVR) Competitors $2.50 +0.04 (+1.63%) As of 08/18/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. DTIL, UNCY, ELYM, PDSB, KLRS, XCUR, CVM, PYRGF, ABVC, and INKTShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Precision BioSciences (DTIL), Unicycive Therapeutics (UNCY), Eliem Therapeutics (ELYM), PDS Biotechnology (PDSB), Kalaris Therapeutics (KLRS), Exicure (XCUR), CEL-SCI (CVM), PyroGenesis Canada (PYRGF), ABVC BioPharma (ABVC), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors Precision BioSciences Unicycive Therapeutics Eliem Therapeutics PDS Biotechnology Kalaris Therapeutics Exicure CEL-SCI PyroGenesis Canada ABVC BioPharma MiNK Therapeutics Precision BioSciences (NASDAQ:DTIL) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Is DTIL or ALVR more profitable? AlloVir has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. AlloVir's return on equity of -71.03% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% AlloVir N/A -71.03%-61.27% Do analysts rate DTIL or ALVR? Precision BioSciences presently has a consensus price target of $47.00, suggesting a potential upside of 879.17%. Given Precision BioSciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to DTIL or ALVR? In the previous week, Precision BioSciences had 7 more articles in the media than AlloVir. MarketBeat recorded 7 mentions for Precision BioSciences and 0 mentions for AlloVir. Precision BioSciences' average media sentiment score of 1.01 beat AlloVir's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Positive AlloVir Neutral Do insiders & institutionals hold more shares of DTIL or ALVR? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, DTIL or ALVR? Precision BioSciences has higher revenue and earnings than AlloVir. Precision BioSciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.82$7.17M-$8.81-0.54AlloVirN/AN/A-$190.42M-$20.23-0.12 Which has more risk & volatility, DTIL or ALVR? Precision BioSciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. SummaryPrecision BioSciences beats AlloVir on 9 of the 15 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.61M$279.88M$5.76B$9.65BDividend YieldN/AN/A3.91%4.09%P/E Ratio-0.12N/A30.7825.12Price / SalesN/A563.86456.64116.46Price / CashN/A22.4425.2228.45Price / Book0.099.579.375.95Net Income-$190.42M-$115.81M$3.26B$265.46M7 Day Performance-6.37%-1.49%1.88%0.96%1 Month Performance4.60%-4.01%3.73%2.47%1 Year Performance-85.84%-9.87%28.93%20.24% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.50+1.6%N/A-85.6%$12.61MN/A-0.12110High Trading VolumeDTILPrecision BioSciences4.2807 of 5 stars$4.39+0.1%$47.00+971.8%-43.9%$52.64M$68.70M-0.51200Positive NewsUNCYUnicycive Therapeutics2.5834 of 5 stars$4.04+0.7%$60.00+1,385.1%+32.0%$51.10M$680K-0.799Trending NewsEarnings ReportELYMEliem TherapeuticsN/A$1.70+1.2%N/A-69.1%$50.58MN/A-3.219Gap UpPDSBPDS Biotechnology2.0991 of 5 stars$1.09+0.9%$9.00+725.7%-61.8%$49.82MN/A-1.1620Earnings ReportKLRSKalaris Therapeutics1.2674 of 5 stars$2.66-0.4%$3.00+12.8%N/A$49.74MN/A0.00110News CoverageEarnings ReportAnalyst RevisionGap UpXCURExicure2.1643 of 5 stars$7.69+1.5%N/A+1,719.4%$49.74M$500K-2.0350News CoveragePositive NewsShort Interest ↓CVMCEL-SCI1.2681 of 5 stars$7.23+2.8%N/A-73.7%$49.72MN/A-15.0543Short Interest ↓PYRGFPyroGenesis CanadaN/A$0.26-5.4%N/A-59.5%$49.68M$9.14M-4.4290ABVCABVC BioPharma0.3981 of 5 stars$2.92+8.3%N/A+374.7%$49.33M$510K-22.3530Earnings ReportINKTMiNK Therapeutics3.1003 of 5 stars$12.10-1.0%$37.50+210.0%+80.5%$48.26MN/A-4.8030Earnings Report Related Companies and Tools Related Companies DTIL Alternatives UNCY Alternatives ELYM Alternatives PDSB Alternatives KLRS Alternatives XCUR Alternatives CVM Alternatives PYRGF Alternatives ABVC Alternatives INKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access